Drug Type Small molecule drug |
Synonyms HQK-1004, VX-105 |
Target |
Mechanism thymidine kinase stimulants(Thymidine kinase stimulants) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H22N4O4 |
InChIKeyHTWPXGKLFMPZHG-WCCKRBBISA-N |
CAS Registry80407-72-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epstein-Barr virus positive Lymphoma | Phase 2 | US | 01 May 2010 | |
Epstein-Barr Virus-Related Lymphoma | Phase 2 | US | 01 Sep 2008 | |
Anemia, Sickle Cell | Phase 2 | US | 01 Sep 1997 | |
Beta-Thalassemia | Phase 2 | US | 01 Sep 1997 | |
Leg Ulcer | Phase 2 | US | 01 Sep 1997 | |
Short Bowel Syndrome | Preclinical | US | 09 Mar 2023 |
Phase 2 | 23 | Standard local care dressing (Standard Local Care Dressing) | tjtdoxpvpa(mzpdqzghon) = nzsebpcyyf iwkdppqdnd (qfarqttifr, xgwjjfiube - ousratteex) View more | - | 31 Mar 2015 | ||
Standard local care dressing+Arginine Butyrate (Arginine Butyrate) | tjtdoxpvpa(mzpdqzghon) = vgijdyfrpw iwkdppqdnd (qfarqttifr, acxicmubob - ewqqrbrdli) View more | ||||||
Phase 2 | 23 | (Standard local care) | qwecbkzbtb(ugnnacqsaq) = giuvieadqv cawupchfsl (vejbzkgtbg ) | - | 01 Dec 2010 | ||
Standard care with Arginine Butyrate | qwecbkzbtb(ugnnacqsaq) = emujwbdjor cawupchfsl (vejbzkgtbg ) | ||||||
Phase 1/2 | 15 | qldkzqsjxe(szdnkuzltf) = icwgdyoyxe zfotbngape (xsvgyowggj ) | - | 15 Mar 2007 | |||
Phase 1/2 | - | anulryyvml(moatuiyqmr) = begtpqkpnj oohvjqdkzi (pfihomeokl ) | - | 20 Jun 2006 |